Search research articles
Contact Us
Filters
Showing results (121-130 of 273) with videos related to
Page
of 28
Sort By:
Blood Cancer Journal
|
February 2, 2023
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors
Deepti Gadi, Stephen P Martindale, Pui Yan Chiu, et al.
British Journal of Haematology
|
January 6, 2016
A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma
Philippe Armand, Robert Redd, Jad Bsat, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 4, 2019
Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation
Clinton Lewis, Haesook T Kim, Lindsey E Roeker, et al.
Cancer Immunology Research
|
October 12, 2021
Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses
Xia Bu, Vikram R Juneja, Carol G Reynolds, et al.
Leukemia & Lymphoma
|
March 26, 2025
A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomas
Mwanasha H Merrill, Robert A Redd, David C Fisher, et al.
Blood
|
May 2, 2023
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
Pier Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 22, 2011
Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts
Yi-Bin Chen, Julie Aldridge, Haesook T Kim, et al.
Blood Cancer Journal
|
June 25, 2026
Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin
Shin Yeu Ong, Lu Chen, Jomel Meeko Manzano, et al.
Blood
|
June 9, 2018
Mass cytometry of Hodgkin lymphoma reveals a CD4<sup>+</sup> regulatory T-cell-rich and exhausted T-effector microenvironment
Fathima Zumla Cader, Ron C J Schackmann, Xihao Hu, et al.
Blood
|
June 20, 2012
A disease risk index for patients undergoing allogeneic stem cell transplantation
Philippe Armand, Christopher J Gibson, Corey Cutler, et al.
Page
of 28
Search research articles
Search
Showing results (121-130 of 273) with videos related to
Sort By:
Page
of 28
Blood Cancer Journal
|
February 2, 2023
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors
Deepti Gadi, Stephen P Martindale, Pui Yan Chiu, et al.
British Journal of Haematology
|
January 6, 2016
A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma
Philippe Armand, Robert Redd, Jad Bsat, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 4, 2019
Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation
Clinton Lewis, Haesook T Kim, Lindsey E Roeker, et al.
Cancer Immunology Research
|
October 12, 2021
Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses
Xia Bu, Vikram R Juneja, Carol G Reynolds, et al.
Leukemia & Lymphoma
|
March 26, 2025
A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomas
Mwanasha H Merrill, Robert A Redd, David C Fisher, et al.
Blood
|
May 2, 2023
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
Pier Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 22, 2011
Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts
Yi-Bin Chen, Julie Aldridge, Haesook T Kim, et al.
Blood Cancer Journal
|
June 25, 2026
Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin
Shin Yeu Ong, Lu Chen, Jomel Meeko Manzano, et al.
Blood
|
June 9, 2018
Mass cytometry of Hodgkin lymphoma reveals a CD4<sup>+</sup> regulatory T-cell-rich and exhausted T-effector microenvironment
Fathima Zumla Cader, Ron C J Schackmann, Xihao Hu, et al.
Blood
|
June 20, 2012
A disease risk index for patients undergoing allogeneic stem cell transplantation
Philippe Armand, Christopher J Gibson, Corey Cutler, et al.
Page
of 28